Appetite measures as correlates of clinical response in mood disorders treated with ketamine: systematic review
Frontiers in Nutrition August 21, 2025 Jakub Słupski, Agnieszka Mechlińska, Adam Włodarczyk et al. 1 citation
Mood disorders, including major depressive disorder (MDD) and bipolar disorder (BP), significantly impact global health, with MDD affecting over 300 million people and BP affecting approximately 2% of the world's population. Ketamine, originally an anesthetic, has emerged as a promising treatment for patients with treatment-resistant depression (TRD), due to its unique pharmacological...